Pete Knox

/Pete Knox

About Pete Knox

This author has not yet filled in any details.
So far Pete Knox has created 24 blog entries.

Quadruple-Negative GIST Tumors May Be More Likely To Harbor NF1 Mutations As Well

In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]

By |2018-10-30T09:41:06-04:00July 19th, 2016|Clinical Trials, News, Research|

Ignyta Announces Results for Potential New Cancer Treatment

Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]

By |2018-10-30T09:42:39-04:00July 12th, 2016|Clinical Trials, News, Research|

Update on Blueprint Medicines Clinical Trial for BLU-285

Recently a number of companies have begun to develop therapeutic options that target some of the rarer mutations in GIST. As there are currently no approved treatments specifically for these patients, this [...]

By |2018-10-30T09:50:21-04:00May 24th, 2016|Clinical Trials, News, Research|

Genetic Alliance Event Invites Collaboration

Genetic Alliance recently held an event in Chapel Hill, N.C. that brought together patient advocates, scientists and representatives from the pharmaceutical industry in a unique “speed-dating” format. Disease advocacy organizations were invited to present briefly [...]

By |2018-10-30T11:28:10-04:00December 16th, 2015|Advocacy, Newsletter|

Adjuvant Imatinib Study Updates Results

A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]

By |2018-10-30T13:56:09-04:00December 16th, 2015|Gleevec, News, Newsletter, Research, Survival Strategies|

Conditional Disease-free Survival after GIST Resection Improves Over Time

In a recent study led by Danielle A Bischof, MD of Johns Hopkins and published in JAMA Surgery, the authors propose a new way of estimating disease-free survival for GIST patients – Conditional Disease-free Survival [...]

By |2019-04-08T09:46:50-04:00March 24th, 2015|News, Risk Assessment|

Recent Posts

Upcoming Events

  1. GDOL Vancouver 2019 Banner

    GIST Day of Learning – Vancouver

    April 27 @ 9:00 AM - 4:00 PM
  2. Samantha Greenberg Webcast
  3. GIST DO IT NJ

    May 4 @ 8:00 AM - 11:00 AM